進階搜尋


  查詢北醫館藏
系統識別號 U0007-1607200911003200
論文名稱(中文) 乳癌的Kruppel-like factor表現和臨床表現的關聯性
論文名稱(英文) The Correlation of Expression of Kruppel-like factors (KLF) and the Clinical Manifestations of the Breast Cancer
校院名稱 臺北醫學大學
系所名稱(中) 臨床醫學研究所
系所名稱(英) Graduate Institute of Clinical Medicine
學年度 97
學期 2
出版年 98
研究生(中文) 陳志榮
研究生(英文) Chih-Chen Chen
學號 M102095030
學位類別 碩士
語文別 英文
口試日期 2009-06-12
論文頁數 85頁
口試委員 指導教授-陳志榮
共同指導教授-林賜恩
委員-賴文福
委員-賴義雄
委員-陳達人
中文關鍵字 乳癌  Kruppel-like factor 
英文關鍵字 Breast cancer  Kruppel-like factor 
學科別分類
中文摘要 乳腺癌是台灣女性因癌症致死的第四位,乳腺癌的發生率有逐年增加和年輕化的趨勢(40歲[含]以下佔29.3%)。近年來,台灣乳腺癌之年齡分佈的狀況和年輕女性所發生之乳腺癌臨床上較具有較侵犯性的表現與西方國家不同。此外,由於乳腺癌本身的異樣性特質,理想的乳腺癌治療方法不僅須依賴傳統的病理組織學、臨床表徵和常用之生物標誌(如ER、PR、HER2/neu),還需探討與發現新的與預後相關的生物因子。由上所述,對台灣婦女乳腺癌的專門研究,成為一個重要的問題。
Kruppel-like factors (KLFs)是一群鋅指樣轉錄因子(Zinc finger like transcription factors),最初被發現和細胞生長的調控有關,目前已知共有超過20種KLFs。最近幾年有越來越多探討KLF在乳腺癌表現的研究,多數研究主要著重於KLF涉及的致癌機轉,而且有數篇研究認為KLF為乳腺癌新的預後因子。在乳腺癌最重要和最被廣泛探討的有KLF4和KLF5,但研究主要局限於西方國家。為了對本地乳腺癌提供更好的治療策略,本研究的目的是探討KLF4和KLF5在台灣婦女乳腺癌的表現情形和與乳腺癌的生物行為相關性。
過去的文獻指出,KLF4同時有抑癌基因和致癌基因的功能,KLF4不僅促進癌細胞的增生,而且還會調節細胞外基質的產生。此外,較侵犯性的臨床行為可能與KLF4在腫瘤細胞內的分布型態有關,在腫瘤細胞有明顯的核表現時,病人預後較差。KLF5也同時具有抑癌基因和致癌基因的特性。KLF5會促進癌細胞增生和轉化,而且具有高表現量的KLF5的乳腺癌病人的預後不良,這現象和HER-2/neu基因及Ki-67的表現量呈正相關性。高表現量的KLF5通常發生在50歲(含)以下的乳腺癌患者身上。
在本研究中,我們使用免疫組織化學方法探討KLF4和KLF5在非腫瘤及腫瘤(含浸潤癌或原位癌)乳腺組織的表現強度和表現型態。並同時統計KLF4和KLF5的表現與乳腺癌組織學特徵、臨床特徵和其他傳統的預後因子的相關性。
本研究共收集了60名乳腺癌患者,其平均年齡為47歲,平均腫瘤大小為2.7公分。臨床表現為第一期的有30%;第二期有43.3%;第三期有21.7%;第四期有5%。經診斷後的平均追蹤時間為27個月(範圍從8至59個月),其中只有一名患者是死於乳腺癌。本研究中90%病例的乳腺癌的組織型態為浸潤性管道癌(Invasive ductal carcinoma, IDC),且66.7%為中度分化。於病灶旁邊管道原位癌(Ductal carcinoma in situ, DCIS)有60%的分化程度為最差等級的。將KLF4和KLF5的免疫組織染色結果與這些病例的臨床表現作關聯性探討時,發現KLF4表現以細胞質和核為主,其中43.3%的病人為腫瘤部分的表現強度比非腫瘤部分強。若腫瘤細胞的KLF4核表現傾向≧25%的病例,有較高的癌症分期(p=0.006),並有較大的腫瘤(最大徑超過2公分,p=0.035)。KLF4的表現也有年齡的相關性,即年齡超過50歲的病例,浸潤癌或原位癌的表現比非腫瘤部分來的更強(p= 0.007),而且,其浸潤性癌的分化也較差(p=0.033)。此外,我們還發現同一病例的浸潤性癌和原位癌之表現有一致性:若原位癌的表現越強,其浸潤性癌的表現也強(p=0.002);核表現的傾向也有一致性(p<0.001)。KLF5表現以細胞質為主,其中58.3%的病人為腫瘤部分(含浸潤癌或原位癌)的表現強度比非腫瘤部分強。就KLF5方面,浸潤性癌若為陰性或弱的細胞質染色時,比較強細胞質表現的乳癌有較好的組織學分化(p=0.035)。另外,同一腫瘤內KLF5的表現在浸潤性癌和原位癌有一致性:若原位癌的表現越強,其浸潤性癌的表現也強(p<0.001);細胞質表現的傾向也具有一致性(p<0.001)。此外,KLF4的表現強度和型態分別和以下因子的表現無相關:動情素接受器(p=0.271和p=0.925),黃體激素接受器(p=0.191和p=0.448),HER-2/neu(p=0.136和p=0.454),p53(p=1.000和p=0.925)和p21 (p=0.572和p=0.367)。KLF5的表現強度和型態分別和以下因子的表現無相關:動情素接受器(p=1.000和p=0.512),黃體激素接受器(p=1.000)和HER-2/neu(p=0.520和p=0.443)。
本研究發現KLF4表現與浸潤性癌的分期,腫瘤大小,病人年紀有正相關性,未能得出和已知文獻中提到KLF4核表現強,其臨床預後較差的結果;另一方面,KLF5表現與浸潤性癌的分化程度有關,我們同時發現到KLF5的核表現主要是局限在非腫瘤性的乳腺組織(16.7%),且沒有任何核染色在原位癌和浸潤性癌發現,已發表的文獻並未提到此現象。雖然,我們目前還不知道這現象代表的生物意義,但這可能代表KLF5有抑癌基因的作用。我們觀察到KLF4和KLF5表現和乳腺癌的臨床表現有關,但其表現與否還無法作為預測乳腺癌的預後和存活率,主要是由於本研究之病例追蹤時間不夠長,無法明確顯示KLF4與KLF5和存活率的相關性,所以精心設計的回顧性研究,配合上長時間的病人追蹤在研究KLF4和KLF5表現與乳腺癌預後及存活率的關聯性是必要的。
英文摘要 Breast cancer is the fourth cause of female cancer deaths in Taiwan with increased incidence and young age tendency (age?T40 years old, 29.3%). In recent years, the distinct age distribution and more aggressive clinical behavior in the young patient are noted in Taiwanese women and this phenomenon is different from that in the Western countries. Besides, due to the heterogeneity of breast cancer, designation of an ideal treatment protocol for breast cancer could not only be based on the traditionally histological, clinical, and biological markers (such as ER, PR and HER-2/neu) but also some new prognostic factors. Therefore, the specific study of breast cancer in Taiwan women becomes an important issue.
Kruppel-like factors (KLF) belong to a group of zinc finger like transcription factors and are involved in regulating cell proliferation. KLFs have more than twenty subtypes. The studies of Kruppel-like factors in breast cancer are increased recently and are mainly focused on their roles in tumorigenesis. The KLFs are considered as new prognostic factors in breast cancers in some studies. Among them, KLF4 and KLF5 are most important and are broadly studied, but most studies are mainly in Western countries. In order to provide better treatment strategies for native breast cancers, the aim of this study is to evaluate the correlation of KLF4 and KLF5 expression with pathologic changes and clinical behaviors of breast cancers in Taiwanese women.
In the literatures, KLF4 has both tumor suppressor gene and oncogene functions. KLF4 can promote the proliferation of cancer cells and also can regulate production of extracellular matrix. More aggressive clinical manifestations may be associated with the cellular location of KLF4 in cancer cells. The patients have poor prognosis when nuclear localization of KLF4 in cancer cells. KLF5 also has both tumor suppressor gene and oncogene functions. KLF5 can facilitate the proliferation and transformation of cancer cells. Increased expression of KLF5 is a poor prognostic factor and is positively correlated with the expression of HER-2/neu and Ki-67 in breast cancer. KLF5 also has increased expression in breast cancer patients younger than 50 years old.
In this study, we used immunohistochemistry method to evaluate both staining intensity and staining pattern of expression of KLF4 and KLF5 in non-tumor and tumor parts (including invasive and in situ cancers) of breast tissues. We also analyzed the associations of expression status of KLF4 and KLF5 with histological features, clinical presentation and other prognostic factors of breast cancer.
We enrolled 60 breast cancer patients with the mean age 47 years old and the mean tumor size was 2.7 cm. The clinical presentation was stage I: 30.0%; stage II: 43.3%; stage III: 21.7%; and stage IV: 5.0%. The follow-up period of these patients ranged from 8 to 59 months (mean 27 months) and only one patient died of disease. Pathologically, most of them were invasive ductal carcinoma (IDC) (90.0%) and showed moderately differentiation (66.7%). The accompanied ductal carcinoma in situ (DCIS), if present, was predominantly highest grade (60.0%). The immunohistochemical study of KLF4 in cancer cells showed cytoplasmic and nuclear expression. The intensity of tumor part was stronger than non-tumor part in 43.3% patients. We evaluated the association of the immunohistochemical results of KLF4 and KLF5 and clinical manifestations of these patients. We found that more KLF4 nuclear expression in tumor cells positively correlated with more advanced stage (p=0.006) and larger size of the tumor (size more than 2 cm in maximal diameter, p=0.035). KLF4 expression was also age-related. KLF4 intensity was stronger in tumor part than non-tumor part in patients older than 50 years old (p=0.007) and, in this setting, the invasive cancer tended to be poorly differentiated (p=0.033). Besides, consistent expression of KLF4 between DCIS and invasive cancers was also found: stronger intensity in DCIS accompanied with stronger intensity in invasive cancers (p=0.002), more predominant nuclear expression in DCIS with more predominant nuclear expression in invasive cancers (p<0.001). The expression of KLF5 in cancer cells was mainly cytoplasmic. The intensity of tumor part was stronger than non- tumor part in 58.3% patients. For KLF5, invasive breast cancers with negative or weak cytoplasmic expression showed better differentiation compared with strong cytoplasmic expression (p=0.035). Consistent expression of KLF5 between DCIS and invasive cancers was also found: stronger intensity in DCIS with stronger intensity in invasive cancers (p<0.001) and more predominant cytoplasmic expression in DCIS with more predominant cytoplasmic expression in invasive cancers (p<0.001). Moreover, there was no association between the following factors and the KLF4 expression intensity and pattern, respectively: ER (p=0.271 and p=0.925), PR (p=0.191 and p=0.448), HER-2/neu (p=0.136 and p=0.454), p53 (p=1.000 and p=0.925), and p21 (p=0.572 and p=0.367). There was also no correlation between the following factors and the KLF5 expression intensity and staining pattern, respectively: ER (p=1.000 and p=0.512), PR (p=1.000 and p=1.000), and HER-2/neu (p=0.520 and p=0.443).
Our study found that KLF4 expression is positive association with tumor stage, tumor size, and age but could not conduct the conclusion that nuclear KLF4 expression was an adverse prognostic factor proposed in the literatures. In the other hand, KLF5 expression was associated with the differentiation of invasive cancers. We also found that KLF5 nuclear localization was mainly restrictedly in non-tumor breast ducts and lobules (16.7%) and loss of nuclear expression in DCIS and invasive cancers, the finding not mentioned in literatures before. Although we didn’t study the biologic function of KLF5, it maybe presented a possible tumor suppressor gene-like function of KLF5. We found that there were associations of KLF4 and KLF5 expressions and clinical manifestations in breast cancers but the expressions of KLF4 and KLF5 were not enough to predict the prognosis and survival rate. The major cause was due to too short follow up period of our patients to exactly evaluate the association of survival rate and expressions of KLF4 and KLF5. Therefore, well-designed retrospective studies with adequate follow up period for studying correlation of expressions of KLF4 and KLF5 and prognosis and survival rate of breast cancers are necessary.
論文目次 致謝 I
目錄 II
縮寫表 (Abbreviations) IV
第一章 中文摘要 (Abstract in Chinese) 1
第二章 英文摘要 (Abstract in English) 4
第三章 緒論 (Introduction) 8
3.1 Breast Cancer in Taiwan 8
3.2 Kruppel-like Factors and Breast Cancer 14
3.3 Kruppel-like Factor 4 (KLF4) and Breast Cancer 16
3.4 Kruppel-like Factor 5 (KLF5) and Breast Cancer 21
3.5 Aims of Our Study 22
第四章 研究方法與材料 (Materials and Methods) 24
4.1 Study Design and Patient Selection 24
4.2 Pathological Evaluation 24
4.3 Immunohistochemistry 25
4.3.1 Immunohistochemistry of KLF4 in Breast
Cancers 27
4.3.2 Immunohistochemistry of KLF5 in Breast
Cancers 28
4.3.3 Immunohistochemistry of p53 and p21 in
Breast Cancers 28
4.3.4 Immunohistochemistry of ER, PR, and
HER-2/neu in Breast Cancers 28
4.4 Statistical Analysis 30
第五章 實驗結果 (Results) 31
5.1 Clinical Characteristics of the Patients 31
5.2 Pathological Evaluation of Breast Cancers 31
5.3 Immunohistochemical Results of KLF4, KLF5, p53,
and p21 in Breast Cancers 32
5.3.1 Immunohistochemical Results of KLF4 in
Breast Cancers 33
5.3.2 Immunohistochemical Results of KLF5 in
Breast Cancers 34
5.3.3 Immunohistochemical Results of p53 and p21
in Breast Cancers 35
5.4 Correlation of Clinical Features, Histological
Pictures, and Immunohistochemical Results of
KLF4, KLF5, p53, p21, ER, PR, and HER2/neu in
Breast Cancers 36
第六章 討論 (Discussion) 39
第七章 結論與展望 (Conclusion and Perspectives) 49
第八章 參考文獻 (References) 50
第九章 圖表 (Tables and Figures) 56
參考文獻 Beckers J, Herrmann F, Rieger S, Drobyshev AL, Horsch M, Hrabé de Angelis M, Seliger B. Identification and validation of novel ERBB2 (HER2, NEU) targets including genes involved in angiogenesis. Int J Cancer 2005 Apr 20; 114(4):590-7.
Bertheau P, Espié M, Turpin E, Lehmann J, Plassa LF, Varna M, Janin A, de Thé H. TP53 status and response to chemotherapy in breast cancer. Pathobiology 2008; 75(2):132-9.
Black AR, Black JD, Azizkhan-Clifford J.Sp1 and krüppel-like factor family of transcription factors in cell growth regulation and cancer. J Cell Physiol 2001 Aug; 188(2):143-60.
Chen C, Bhalala HV, Qiao H, Dong JT.A possible tumor suppressor role of the KLF5 transcription factor in human breast cancer. Oncogene 2002 Sep 26; 21(43):6567-72.
Chen C, Zhou Y, Zhou Z, Sun X, Otto KB, Uht RM, Dong JT. Regulation of KLF5 involves the Sp1 transcription factor in human epithelial cells. Gene 2004 Apr 14; 330:133-42.
Chen C, Sun X, Guo P, Dong XY, Sethi P, Cheng X, Zhou J, Ling J, Simons JW, Lingrel JB, Dong JT. Human Kruppel-like factor 5 is a target of the E3 ubiquitin ligase WWP1 for proteolysis in epithelial cells. J Biol Chem 2005 Dec 16; 280(50):41553-61.
Chen C, Zhou Y, Dong JT. KLF5: Kruppel-like factor 5 (intestinal). Atlas Genet Cytogenet Oncol Haematol October 2006.
(URL: http://AtlasGeneticsOncology.org/Genes/KLF5ID41074ch13q21.html)
Cheng SH, Tsou MH, Liu MC, Jian JJ, Cheng JC, Leu SY, Hsieh CY, Huang AT. Unique features of breast cancer in Taiwan. Breast Cancer Res Treat 2000 Oct; 63(3):213-23.
Clarke ND, Berg JM. Zinc fingers in Caenorhabditis elegans: finding families and probing pathways. Science 1998 Dec 11; 282(5396):2018-22.
Dang DT, Pevsner J, Yang VW. The biology of the mammalian Krüppel-like family of transcription factors .Int J Biochem Cell Biol 2000; 32(11-12):1103–21.
Elledge RM, Allred DC. Prognostic and predictive value of p53 and p21 in breast cancer. Breast Cancer Res Treat 1998; 52(1-3):79-98.
Faratian D, Bartlett J. Predictive markers in breast cancer – the future. Histopathology 2008; 52: 91–8.
Foster KW, Ren S, Louro ID, Lobo-Ruppert SM, McKie-Bell P, Grizzle W, Hayes MR, Broker TR, Chow LT, Ruppert JM. Oncogene expression cloning by retroviral transduction of adenovirus E1A-immortalized rat kidney RK3E cells: transformation of a host with epithelial features by c-MYC and the zinc finger protein GKLF. Cell Growth Differ 1999 Jun; 10(6):423-34.
Foster KW, Frost AR, McKie-Bell P, Lin CY, Engler JA, Grizzle WE, Ruppert JM. Increase of GKLF messenger RNA and protein expression during progression of breast cancer. Cancer Res 2000 Nov 15; 60(22):6488-95.
Ghaleb AM, Nandan MO, Chanchevalap S, Dalton WB, Hisamuddin IM, Yang VW. Krüppel-like factors 4 and 5: the yin and yang regulators of cellular proliferation. Cell Res 2005 Feb; 15(2):92-6.
Graham JD, Yager ML, Hill HD, Byth K, O'Neill GM, Clarke CL. Altered progesterone receptor isoform expression remodels progestin responsiveness of breast cancer cells. Mol Endocrinol 2005 Nov; 19(11):2713-35.
Guo H, Lin Y, Zhang H, Liu J, Zhang N, Li Y, Kong D, Tang Q, Ma D. Tissue factor pathway inhibitor-2 was repressed by CpG hypermethylation through inhibition of KLF6 binding in highly invasive breast cancer cells. BMC Mol Biol 2007 Dec 3; 8:110.
Kikuchi A. Regulation of beta-catenin signaling in the Wnt pathway. Biochem Biophys Res Commun 2000 Feb 16; 268(2):243-8.
Kumar V, Abbas A, Fausto N. Robbins and Cotran. Pathologic basis of disease, 7th edition, Philadelphia: Elsevier Saunders. 2005; pp:1120-52.
Miller KA, Eklund EA, Peddinghaus ML, Cao Z, Fernandes N, Turk PW, Thimmapaya B, Weitzman SA. Kruppel-like factor 4 regulates laminin alpha 3A expression in mammary epithelial cells. J Biol Chem 2001 Nov 16; 276(46):42863-8.
Pandya AY, Talley LI, Frost AR, Fitzgerald TJ, Trivedi V, Chakravarthy M, Chhieng DC, Grizzle WE, Engler JA, Krontiras H, Bland KI, LoBuglio AF, Lobo-Ruppert SM, Ruppert JM. Nuclear localization of KLF4 is associated with an aggressive phenotype in early-stage breast cancer. Clin Cancer Res 2004 Apr 15; 10(8):2709-19.
Payne SJ, Bowen RL, Jones JL, Wells CA. Predictive markers in breast cancer-the present. Histopathology 2008; 52:82-90.
Rayala SK, Molli PR, Kumar R. Nuclear p21-activated kinase 1 in breast cancer packs off tamoxifen sensitivity. Cancer Res 2006 Jun 15; 66(12):5985-8.
Rosen PP. Rosen’s Breast Pathology. In: Invasive duct carcinoma: assessment of Prognosis, morphologic prognostic markers, and tumor growth rate. Philadelphia: Lippincott Williams & Wilkins; 2009; 358-404.
Rowland BD, Bernards R, Peeper DS. The KLF4 tumor suppressor is a transcriptional repressor of p53 that acts as a context-dependent oncogene. Nat Cell Biol 2005 Nov; 7(11):1074-82.
Rowland BD, Peeper DS. KLF4, p21 and context-dependent opposing forces in cancer. Nat Rev Cancer 2006 Jan; 6(1):11-23.
Shen YC, Chang CJ, Hsu C, Cheng CC, Chiu CF, Cheng AL. Significant difference in the trends of female breast cancer incidence between Taiwanese and Caucasian Americans: implications from age-period-cohort analysis. Cancer Epidemiol Biomarkers Prev 2005 Aug; 14(8):1986-90.
Schnitt SJ, Collins LC. Biopsy interpretation of the breast. In: Invasive breast cancer. Philadelphia: Lippincott Williams & Wilkins; 2009; 249-322.
Staalesen V, Knappskog S, Chrisanthar R, Nordgard SH, Løkkevik E, Anker G, Ostenstad B, Lundgren S, Risberg T, Mjaaland I, Gram IT, Kristensen VN, Børresen-Dale AL, Lillehaug JR, Lønning PE. The novel p21 polymorphism p21G251A is associated with locally advanced breast cancer. Clin Cancer Res 2006 Oct 15; 12(20 Pt 1):6000-4.
Tavassoli FA, Peter Devilee. World health organization classification of Tumours. Pathology& genetics. Tumours of the breast and female genital organs. Lyon: IARC Press; 2003; 15.
Talley L, Chieng DC, Bell WC, Grizzle WE, Frost AR. Immunohistochemical detection of EGFR, p185 (erbB-2), Bcl-2 and p53 in breast carcinomas in pre-menopausal and post-menopausal women. Biotech Histochem 2008 Feb; 83(1):5-14.
Tong D, Czerwenka K, Heinze G, Ryffel M, Schuster E, Witt A, Leodolter S, Zeillinger R. Expression of KLF5 is a prognostic factor for disease-free survival and overall survival in patients with breast cancer. Clin Cancer Res 2006 Apr 15; 12(8):2442-8.
Turner J, Crossley M. Mammalian Krüppel-like transcription factors: more than just a pretty finger. Trends Biochem Sci 1999 Jun; 24(6):236-40.
Vannini I, Zoli W, Tesei A, Rosetti M, Sansone P, Storci G, Passardi A, Massa I, Ricci M, Gusolfino D, Fabbri F, Ulivi P, Brigliadori G, Amadori D, Bonafe M. Role of p53 codon 72 arginine allele in cell survival in vitro and in the clinical outcome of patients with advanced breast cancer. Tumour Biol 2008; 29(3):145-51.
Wang X, Zheng M, Liu G, Xia W, McKeown-Longo PJ, Hung MC, Zhao J. Krüppel-like factor 8 induces epithelial to mesenchymal transition and epithelial cell invasion. Cancer Res 2007 Aug 1; 67(15):7184-93.
Wei X, Xu H, Kufe D.Human mucin 1 oncoprotein represses transcription of the p53 tumor suppressor gene. Cancer Res 2007 Feb 15; 67(4):1853-8.
Yancy HF, Mason JA, Peters S, Thompson CE 3rd, Littleton GK, Jett M, Day AA. Metastatic progression and gene expression between breast cancer cell lines from African American and Caucasian women. J Carcinog 2007 May 1; 6:8.
Zhang L, Wali A, Ramana CV, Rishi AK. Cell growth inhibition by okadaic acid involves gut-enriched Kruppel-like factor mediated enhanced expression of c-Myc. Cancer Res.2007 Nov 1; 67(21):10198-206.
Zhao Y, Hamza MS, Leong HS, Lim CB, Pan YF, Cheung E, Soo KC, Iyer NG. Kruppel-like factor 5 modulates p53-independent apoptosis through Pim1 survival kinase in cancer cells. Oncogene 2008 Jan 3; 27(1):1-8.
論文全文使用權限
  • 不同意授權瀏覽/列印電子全文服務。


  • 若您有任何疑問,請與我們聯絡!
    臺北醫學大學 圖書館 簡莉婷
    E-mail:etds@tmu.edu.tw
    Tel:(02) 2736-1661 ext.2519
    Fax:(02) 2737-5446